|
|
 |
|
Viewing report
|
|
|
|
Oncology Review and Outlook 2010
UBM Canon, June 2010, Pages: 198
Cancer is the second-leading cause of death in the United States. The opportunity to improve upon current oncology treatments is significant as these medications are, on average, only 25% effective in the advanced disease setting. The urgent need for effective cancer diagnostics and treatments is forecasted to increase as the population ages. Presently, more than 800 drugs are under investigation for cancer.
The amount of oncology drugs in the overall pharma/biotech product pipeline is more than twice the number of any other therapeutic area. Company developers as well as clinicians are searching for better approaches to target tumors. For instance, a new generation of cancer therapeutics are using the immune system. Many emerging cancer treatments have the potential to become blockbuster brands.
This special report focuses on the market leaders for oncology as well as the products in development anticipated to head this therapeutic area in the years to come. This compilation’s prescription-product pipeline details the following information for each medicine: chemical or substance composition, intended indication, class of drug, clinical status, region of development, and the product developer/intended marketer. Pipeline status details preclinical development, Phase I, Phase I/II, Phase II, Phase II/III, Phase III, and awaiting approval. Regions of development include the United States, Europe, and Japan. A directory of oncology prescription-drug developers and marketers is included.
Additionally provided in this report is a listing of oncology medical-device entries, sorted by device class, as well as a directory of medical-device companies associated with the cancer field.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Transdermal Medicine Review and Outlook 2011
Vaccines Review and Outlook 2010
Pain Management Review and Outlook 2011
Dementia: Causes, Treatments, and Outlook 2011
Women's Health Review and Outlook 2011
Anti-Infectives and Antimicrobials Review and Outlook 2011
Personalized Medicine & Orphan Drugs Review and Outlook 2010
Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules
Personalized Medicine - Scientific and Commercial Aspects
The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
|
|
|
|
